Trials / Unknown
UnknownNCT05266768
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#
An Open, Single-arm Clinical Study Evaluating the Safety and Efficacy of IBI346 Infusion in Relapsed/Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Chunrui Li · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open label, single-arm clinical study evaluating the safety and efficacy of IBI346 infusion in relapsed/refractory multiple myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI346 | IBI346 Antibody and IBI346 CAR-T cell injection |
Timeline
- Start date
- 2022-04-28
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
- First posted
- 2022-03-04
- Last updated
- 2022-11-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05266768. Inclusion in this directory is not an endorsement.